Selected scientific papers
This section contains a selection of Dr. Breggin's scientific articles spanning 1964 to the present. They can be arranged chronologically in order to facilitate an overview of his work over the years.
Risks and Mechanism of Action of Stimulants 11/16/1998
Risks and Mechanism of Action of Stimulants. NIH Consensus Development Conference on Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder, November 16-18, 1998.
Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptics (German) 03/30/1990
"Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptics: Evidence, Etiology, Implications." Journal of Mind Behavior, 11:425-464, 1990. German Edition
Breggin, P.R. (1992). A Case of Fluoxetine-induced Stimulant Side Effects with Suicidal Ideation Associated with a Possible Withdrawal Syndrome ("Crashing"). International Journal of Risk & Safety in Medicine, 3, 325-328.
"Electroshock: Scientific, Ethical, and Political Issues." International Journal of Risk & Safety In Medicine, 11:5-40, 1998.
A dangerous assignment (2001) 03/01/2001
"A dangerous assignment," In Howard Rosenthal (Ed.). Favorite Counseling and Therapy Homework Assignments: Leading Therapists Share their Most Creative Strategies, pp. 58-59. Philadelphia: Brunner Routledge, 2001.
International Journal of Risk & Safety in Medicine 22 (2010) 89-92.
Peter R. Breggin
Abstract: Electroconvulsive therapy (ECT) and the machines that deliver it have never been tested for safety and efficacy in order to receive approval from the FDA. The American Psychiatric Association and ECT advocates protested when the FDA took steps to classify the machines as posing “an unreasonable risk of illness or injury”, which would have required their testing before approval. Without requiring this testing, the FDA is now preparing to classify the treatment and the machines as safe. This article reviews evidence demonstrating that ECT is very harmful to the brain and mind, and concludes that the FDA should demand the usual testing, starting with animals, that is required before psychiatric treatments and machines are approved for marketing and use.
"Empowering Social Work in the Era of Biological Psychiatry." (2001) [The annual Ephraim Lisansky ecture of the University of Maryland School of Social Work.] Ethical Human Sciences and Services, :197-206.
From Prozac to Ecstasy: implications of new evidence for drug-induced brain damage (2001) 01/01/2001
"From Prozac to Ecstacy: The Implication of New Evidence for Drug-Induced Brain Damage." Ethical Human Sciences and Services, 3: 3-5, 2001.
Psychiatric drug-induced Chronic Brain Impairment (CBI): Implications for longterm treatment with psychiatric medication. International Journal of Risk & Safety in Medicine, 23: 193-200.
Peter R. Breggin, MD
Abstract: Understanding the hazards associated with long-term exposure to psychiatric drugs is very important but rarely emphasized in the scientific literature and clinical practice. Drawing on the scientific literature and clinical experience, the author describes the syndrome of Chronic Brain Impairment (CBM) which can be caused by any trauma to the brain including Traumatic Brain Injury (TBI), electroconvulsive therapy (ECT), and long-term exposure to psychiatric medications. Knowledge of the syndrome should enable clinicians to more easily identify long-term adverse effects caused by psychiatric drugs while enabling researchers to approach the problem with a more comprehensive understanding of the common elements of brain injury as they are manifested after long-term exposure to psychiatric medications. Treatment options are also discussed.
"What Psychologists and Psychotherapists Need to Know About ADHD and Stimulants." Changes: An International Journal of Psychology and Psychotherapy, 18:13-23, Spring 2000.